Literature DB >> 16793756

Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood.

C Watala1, J Golański, M A Boncler, T Pietrucha, K Gwoździński.   

Abstract

Membrane lipid fluidity (MLF) is thought to play a crucial role in signal transduction and is believed to affect the responsiveness of blood platelets. In a recent study it was demonstrated that EDTA, used as the blood anticoagulant, brought about a significant increase in expression of GMP-140 antigen, and this effect was accompanied by a significant increase in platelet MLF. Moreover, this spontaneous EDTA-driven platelet activation was vastly attenuated in the presence of tissue-type plasminogen activator, which is also known to affect platelet MLF. The hypothesis was raised that the modulation of platelet membrane fluidity by EDTA might underlie platelet spontaneous activation in the presence of EDTA. To further explore the possible molecular mechanism(s) of the EDTA-dependent triggering of signal transduction pathway(s) in human blood platelets, we monitored the extent of spontaneous platelet activation in the presence of EDTA and selected platelet membrane 'fluidizers' and 'rigidizers'. A reduction in the EDTA-dependent platelet release and activation was noted, not only in the presence of rt-PA (by over 50%, P < 0.001), which acted as a rigidizer of platelet membrane fluidity (ESR h+1/h0 ratios of 5-DOXYL-Ste and 12-DOXYL-Ste decreased by 6.2%, P<< 0.0001, and 3.8%, P < 0.02, respectively), but also in the presence of other modulators of MLF, regardless of their fluidizing or rigidizing effects. Both rigidizers (procaine and lidocaine, 5-DOXYL-Ste h+1/h0 reduced by up to 6.5%, 12-DOXYL-Ste h+1/h0- by up to 4.5%, P < 0.02 or less) and fluidizers (benzyl alcohol, ethanol, 12-DOXYL-Ste h+1/h0 increased by 17.8% and 6.1%, respectively, P <<0.0001) of platelet membranes significantly depressed platelet activation (respectively, down to 1.1%, 7.7%, 6.7% and 8.5% vs control EDTA 22.9% of CD62-positive platelets). We suggest that EDTA induces alterations in membrane glycoprotein structure and affect MLF by altering lipid-protein interactions, and thus triggers signal transduction in the course of platelet activation. The resulting displacements in platelet membrane proteins, dislocation of membrane components and/or distortion of lipid-protein interactions could generate an 'outside-in' signalling that is mediated by the altered platelet MLF. Overall, it is likely that interference with the structure and conformation of selected domains of platelet membrane proteins might be the crucial mechanism by which EDTA leads to exaggerated activation of platelets in whole blood.

Entities:  

Year:  1998        PMID: 16793756     DOI: 10.1080/09537109876564

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  13 in total

1.  Effects of Ibrutinib on biophysical parameters of platelet in patients with chronic lymphocytic leukaemia.

Authors:  Viola Maria Popov; Christien Oktaviani Matei; Meilin Omer; Minodora Onisai; Mircea Bogdan Matei; Tudor Savopol; Horia Bumbea; Mihaela G Moisescu
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.

Authors:  Weifei Zhu; Wei Li; Roy L Silverstein
Journal:  Blood       Date:  2012-03-19       Impact factor: 22.113

Review 3.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 4.  Platelet function profiles in patients with diabetes mellitus.

Authors:  Fabiana Rollini; Francesco Franchi; Ana Muñiz-Lozano; Dominick J Angiolillo
Journal:  J Cardiovasc Transl Res       Date:  2013-02-13       Impact factor: 4.132

5.  The relationship between levels of von Willebrand factor and mean platelet volume in subjects with isolated impaired fasting glucose.

Authors:  Feyzi Bostan; Erkan Coban
Journal:  Med Sci Monit       Date:  2011-06

6.  A multiscale model for multiple platelet aggregation in shear flow.

Authors:  Prachi Gupta; Peng Zhang; Jawaad Sheriff; Danny Bluestein; Yuefan Deng
Journal:  Biomech Model Mechanobiol       Date:  2021-03-29

7.  High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study.

Authors:  Gadi Shlomai; Tal Haran-Appel; Tal Sella; Yoni Grossman; Hagit Hauschner; Nurit Rosenberg; Ehud Grossman
Journal:  Cardiovasc Diabetol       Date:  2015-06-12       Impact factor: 9.951

8.  Characterization of procoagulant extracellular vesicles and platelet membrane disintegration in DMSO-cryopreserved platelets.

Authors:  Tseday Z Tegegn; Silvia H De Paoli; Martina Orecna; Oumsalama K Elhelu; Samuel A Woodle; Ivan D Tarandovskiy; Mikhail V Ovanesov; Jan Simak
Journal:  J Extracell Vesicles       Date:  2016-05-04

Review 9.  Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.

Authors:  Raminderjit Kaur; Manpreet Kaur; Jatinder Singh
Journal:  Cardiovasc Diabetol       Date:  2018-08-31       Impact factor: 9.951

10.  Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Authors:  Ornella Bosco; Barbara Vizio; Gabriella Gruden; Martina Schiavello; Bartolomeo Lorenzati; Paolo Cavallo-Perin; Isabella Russo; Giuseppe Montrucchio; Enrico Lupia
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.